ascopubs.org

Expression of hypoxia-inducible factor-1 alpha is associated with an unfavorable prognosis in non-small cell lung cancer

Hypoxia-related markers in the plasma of patients with advanced non-small cell lung cancer (NSCLC) and survival from chemotherapy: Southwest Oncology Group (SWOG) S0003 No significant financial ...
ascopubs.org

Phase 3 LITESPARK-022: Pembrolizumab (pembro) plus hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan as adjuvant treatment for clear cell renal cell carcinoma (ccRCC).

LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib in patients with advanced renal cell carcinoma. Phase 1b/2 study of combination 177Lu girentuximab plus ...
Business Wire

FDA Approves Merck’s Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitor WELIREG™ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved WELIREG, an oral ...
The American Journal of Managed Care

Study Uses NIRS to Assess Hypoxia-Related Brain Function Impairment in Patients With MS

Ateyeh Soroush, a PhD candidate at the University of Calgary, explains her ongoing study utilizing near-infrared spectroscopy (NIRS) to investigate hypoxia-related brain function impairment in ...